Benzo[b]thiophene-based histone deacetylase inhibitors

David J. Witter, Sandro Belvedere, Liqiang Chen, J. Paul Secrist, Ralph T. Mosley, Thomas A. Miller

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Benzo[b]thienyl hydroxamic acids, a novel class of histone deacetylase (HDAC) inhibitors, were identified via a targeted screen of small molecule hydroxamic acids. Various substitutions were explored in the C5- and C6-positions of the benzo[b]thiophene core to characterize SAR and develop optimal inhibitors. It was determined that substitution at the C6-position of the benzo[b]thiophene core with a three-atom spacer yielded optimal HDAC1 inhibition and anti-proliferative activity in murine erythroleukemia (SC-9) cells.

Original languageEnglish (US)
Pages (from-to)4562-4567
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume17
Issue number16
DOIs
StatePublished - Aug 15 2007

Keywords

  • Anticancer drug
  • Benzo[b]thiophene
  • HDAC
  • HDAC inhibitor
  • Histone deacetylase inhibitor
  • Hydroxamic acids
  • SAHA

Fingerprint Dive into the research topics of 'Benzo[b]thiophene-based histone deacetylase inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Witter, D. J., Belvedere, S., Chen, L., Secrist, J. P., Mosley, R. T., & Miller, T. A. (2007). Benzo[b]thiophene-based histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 17(16), 4562-4567. https://doi.org/10.1016/j.bmcl.2007.05.091